Publications & Reports

The impact of markers of HIV infection on change in liver stiffness in people with HIV and hepatitis C virus co-infection after treatment and cure of hepatitis C.

van Santen DK, Agius PA, Sasadeusz J, Fairley KC, Sievert W, Gane E, Iser D, O'Reilly M, Medland NA, Moore R, Hellard ME, Hoy JF, Doyle JS
Burnet Institute, Melbourne, Australia.


BACKGROUND: Markers of HIV disease severity are associated with increased liver fibrosis in HIV/Hepatitis C virus (HCV) co-infected individuals. HCV treatment may reverse liver fibrosis, but evidence among HIV/HCV-coinfected populations and the impact of HIV parameters on fibrosis regression is limited. We aimed to assess the influence of surrogate markers of HIV-infection and other determinants of liver stiffness before hepatitis C virus (HCV) treatment and changes after HCV cure in people living with HIV (PLHIV). METHODS: We used data from an HCV treatment implementation study aiming for HCV micro-elimination among gay and bisexual men with HIV in Melbourne, Australia (co-EC Study). We obtained liver stiffness measurements (LSM) before and after direct-acting antiviral treatment using transient elastography (FibroScan). Linear mixed models were used to evaluate determinants of pre-treatment LSM and changes in LSM following cure with duration in years between pre- and post-LSM assessment as main exposure variable. RESULTS: Al least one LSM was available in 173 participants, and 98 participants had two LSMs. Median pre- and post-treatment LSMs were 5.7 and 5.1 kilopascal (kPa), respectively. Median time between transient elastography measurements was 1.3 years (Interquartile range=0.9-2.1). In multivariable analysis, longer duration of known HIV infection, a lower CD4 and CD8 T-cell count and hazardous alcohol consumption were associated with higher LSM values prior to treatment initiation. Successfully treated patients had a 6% (95%CI= -10,-2%) annual decrease (0.34 kPa predicted decrease) in LSM following cure. Changes in LSM values did not depend on any of the pre-treatment HIV markers or other factors. CONCLUSION: Low levels of liver stiffness were observed prior to treatment initiation and a small decrease (6%) in LSM following HCV cure in PLHIV. No clear predictors affecting change in LSM following cure were found in this study, including markers of HIV infection. However, markers of advanced HIV immunodeficiency and hazardous alcohol consumption remained associated with higher LSM values even after HCV cure.

Link to publisher’s web site


  • Journal: Journal of Acquired Immune Deficiency Syndromes
  • Published: 24/08/2020
  • Volume: 85
  • Issue: 5
  • Pagination: e81-e89